1 / 9

Ombitasvir-Paritaprevir - Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II

Explore the study design, regimens, drug dosing, results, adverse events, and conclusions of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + Ribavirin in GT1 SAPPHIRE-II. Data from Zeuzem S. et al. N. Engl. J. Med. 2014;370:1604-14.

winchesterm
Download Presentation

Ombitasvir-Paritaprevir - Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  2. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II: Study Design Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  3. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II: Regimens 0 12 24 36 Week Double blind Ombitasvir-Paritaprevir-RTV and Dasabuvir + Ribavirin Active N = 297 SVR12 Open label (data pending) Placebo Ombitasvir-Paritaprevir-RTV and Dasabuvir + Ribavirin PlaceboN = 97 SVR12 RTV = Ritonavir Drug DosingOmbitasvir-Paritaprevir-Ritonavir (25/150/100 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  4. Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir + RBV in GT1SAPPHIRE-II Study: Baseline Characteristics Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  5. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II: Results SAPPHIRE-II: Results by Genotype 1 Subtype 286/297 166/173 119/123 Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  6. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II: Results SAPPHIRE-II: Results by Prior Treatment Response 286/297 82/86 65/65 139/146 Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  7. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II Study: Key Adverse Events Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  8. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1SAPPHIRE-II: Conclusions Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related